Ulrich Freudensprung
Baar, ZG, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study.
Journal: Rheumatology advances in practice
Published: September 28, 2022
PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar SB2: a 12-month analysis.
Journal: Therapeutic advances in gastroenterology
Published: February 28, 2022
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Journal: PharmacoEconomics
Published: October 12, 2021
Efficacy and safety of fumaric acid esters in young patients aged 10-17 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial.
Journal: The British journal of dermatology
Published: December 12, 2020
Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study.
Journal: Multiple sclerosis and related disorders
Published: January 17, 2020
BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis.
Journal: Clinical and experimental rheumatology
Published: September 30, 2019
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review.
Journal: Rheumatology and therapy
Published: July 02, 2019
Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
Journal: Journal of neurology
Published: May 08, 2018
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 07, 2016
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
Journal: The Lancet. Oncology
Published: October 03, 2014
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: October 03, 2014
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 02, 2014
Last Updated: 09/26/2026